{"id":"W2120171585","doi":"10.1016/j.ejca.2013.02.012","title":"Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours","year":2013,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Ottawa Hospital","funders":"","keywords":"Medicine; Erlotinib; Rash; T790M; Pharmacodynamics; Pharmacokinetics; Adverse effect; Pharmacology; Internal medicine; Epidermal growth factor receptor; Cohort; Discontinuation; Oncology; Cancer; Gefitinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001517798,0.00212617,0.003132077,0.0006686517,0.0005498024,0.001321182,0.001103925,0.001485797,0.004064361],"category_scores_gemma":[0.0008054589,0.0009366896,0.002042865,0.0006608964,0.001441762,0.001042433,0.0004166188,0.00393267,0.001356282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001235939,"about_ca_system_score_gemma":0.002028013,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002681731,"about_ca_topic_score_gemma":0.007125996,"domain_scores_codex":[0.9995452,0.0001855451,0.00002065772,0.00007624004,0.00003990502,0.0001325184],"domain_scores_gemma":[0.9994437,0.00007298611,0.0000796844,0.00004018486,0.00003464511,0.0003286912],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8042635,0.04788624,0.004621686,0.0009538211,0.002462669,0.0003072252,0.0003441001,0.004560751,0.04575134,0.0007401598,0.007957369,0.08015112],"study_design_scores_gemma":[0.6633878,0.3148808,0.01183928,0.00004325681,0.0008402045,0.0003054103,0.00008721314,0.00154959,0.002610192,0.0004290588,0.003976293,0.00005093034],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9843627,0.003895645,0.0009971772,0.001015929,0.0003252967,0.002620831,0.001907335,0.0002108494,0.004664227],"genre_scores_gemma":[0.9781861,0.004487767,0.002106561,0.001634242,0.0003147383,0.002273612,0.0046813,0.00007521887,0.006240492],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004064361,"threshold_uncertainty_score":0.01359659,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03850557109698171,"score_gpt":0.3869098973173942,"score_spread":0.3484043262204125,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}